4 results about "Seizure activity" patented technology

Methods, systems, and apparatus for determining probabilistic measures of seizure activity (PMSA) values based on a plurality of seizure detection algorithms and / or body signals used as inputs by the seizure detection algorithms. Use of the PMSA values to detect seizure activity based on a consensus of the algorithms and / or body signals, and / or warn, log, administer a therapy, or assess the efficacy of a therapy.

Methods and apparatus for preventing seizure activity in an environment using a computer vision system deployed within the environment are described. One example method includes detecting a seizure trigger within the environment via one or more camera devices deployed in the environment. At least one user associated with the environment that is susceptible to the seizure trigger is identified. Information associated with the seizure trigger is transmitted to a computing device associated with the at least one user.

A method of estimating the probability of a seizure in a subject, the method comprising: receiving historical data associated with epileptic events experienced by the subject over a first time period, the historical data comprising physiological data associated with each epileptic event and a time at which each epileptic event occurred; generating a temporal probability model of future epileptic events based on the time of each of the epileptic events, the temporal probability model representing a probability of a future seizure occurrence in each of a plurality of time windows; generating a probabilistic model based on the physiological data associated with each epileptic event; weighting the probabilistic model based on the temporal probability model to generate a weighted probabilistic model of future seizure activity; and outputting an estimate of seizure probability in the subject using the weighted probabilistic model.

Provided herein is a method of treating epileptic seizure activity by administering to a subject in need thereof a therapeutically effective amount of a cell composition comprising pluripotent stem cell-derived, MGE-type inhibitory (e.g., GABAergic) neuronal cells. In some embodiments, at least 90% of the cells in the composition are post-mitotic cells. In some embodiments, at least 50% of the cells in the composition express LHX6, ERBB4, and GAD1.